Please login to the form below

Not currently logged in
Email:
Password:

Johan Heylen leaves GSK for Ablynx

He joins Nanobody specialist as chief commercial officer

edit-Johan-Heylen_Chief-Commercial-Officer_AblynxAblynx has named former GlaxoSmithKline (GSK) executive Johan Heylen as chief commercial officer.

Heylen spent 17 years at GSK, serving most recently as executive director, global commercial lead for its cancer immunotherapeutics division.

In this role he headed the global commercial teams of GSK and was responsible for the development and implementation of the launch strategy for several drugs, including Rotarix, Priorix and Varilix.

Heylen now heads commercial operations at Ablynx, growing biopharma specialising in the development of Nanobodies, tiny fragments of antibodies with therapeutic potential.

He said: "Ablynx has an extraordinary pipeline of products based on its unique Nanobody discovery platform, validated by an impressive list of partners.

“I look forward to working with the first-class team to support the company as it moves to the next stage of development and begins to anticipate the commercialisation of the first Nanobody-based therapeutics."

Heylen also has experience at Servier and Wyeth having started his career in healthcare as a pharmacist.

20th November 2014

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics